Financing Details - Foghorn Therapeutics Inc. closed a $50 million registered direct financing at a 30% premium, selling 2,030,314 shares at $6.71 per share [1] - The offering included pre-funded warrants for up to 5,421,250 shares at $6.7099 each and series warrants for up to 3,725,782 shares at $13.42 and another 3,725,782 shares at $20.13 [1] - The gross proceeds from the offering were approximately $50 million, excluding proceeds from the exercise of series warrants [1] Investor Participation - Existing shareholders such as BVF Partners, Deerfield Management, Flagship Pioneering, and a leading biotech mutual fund participated in the financing [2] - No underwriter or placement agent was involved in the offering [2] Company Overview - Foghorn Therapeutics is focused on developing a new class of medicines that target genetically determined dependencies within the chromatin regulatory system [4] - The company utilizes its Gene Traffic Control platform to identify and validate potential drug targets, with multiple product candidates in oncology [4]